|
|
 | | | |
- close
- close
- close
- close
| |||||||||
This excerpt taken from the ELN 20-F filed Feb 26, 2009. (d) Maxipime
and Azactam asset impairment
The Maxipime and Azactam asset impairment charge
of $52.2 million was related to the launch of a generic
formulation of Maxipime in June 2007 and the anticipated
approval of a generic form of Azactam. As a direct
result, we revised the projected future cumulative undiscounted
cash flows. The revised projected cumulative undiscounted cash
flows were lower than the intangible assets’ carrying value
thus indicating the intangible assets were not recoverable.
Consequently, the impairment charge was calculated as the excess
of the carrying value over the discounted net present value. The
remaining net intangible assets’ carrying value was
amortized, on a straight-line basis, through December 31,
2007.
This excerpt taken from the ELN 20-F filed Feb 28, 2008. (A) Maxipime
and Azactam asset impairment
The Maxipime and Azactam asset impairment charge
of $52.2 million is related to the approval of a first
generic formulation of Maxipime (cefepime hydrochloride)
in June 2007 and the anticipated approval of a generic form of
Azactam. For additional information, refer to
Note 15.
| EXCERPTS ON THIS PAGE:
|
| |||||||
